Formula of probiotics for inhibiting pathogenic bacteria of colorectal cancer and screening method thereof

A technology for colorectal cancer and a screening method, applied in the field of biomedicine, can solve the problems of inability to use probiotics against colorectal cancer pathogenic bacteria, poor colonization ability, etc., so as to alleviate the serious threat to human health and the ecological environment , excellent performance, universal results

Active Publication Date: 2020-01-21
君维安(武汉)生命科技有限公司
View PDF7 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Chinese patent CN107937504A discloses a screening method for feeding probiotics resistant to pig E. coli infection, comprising the following steps: screening of piglets infected with E. coli and disease-resistant piglets and collection of intestinal content samples; High-throughput sequencing of intestinal microbiota of piglets and disease-resistant piglets; comparative analysis of intestinal microbial metagenomics of piglets with E. coli infection and disease-r

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Formula of probiotics for inhibiting pathogenic bacteria of colorectal cancer and screening method thereof
  • Formula of probiotics for inhibiting pathogenic bacteria of colorectal cancer and screening method thereof
  • Formula of probiotics for inhibiting pathogenic bacteria of colorectal cancer and screening method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] S1. Constructed the human gut microbiome online warehouse (GMrepo, http: / / gmrepo.humangut.info / home) database, searched and downloaded the metagenomic data of normal people and colorectal cancer patients in the database, and obtained The double-end sequencing information (ENAaccession ID: ERP005534) of intestinal flora metagenomics (ENAaccession ID: ERP005534) of colon cancer patients (53 cases) and healthy people (61 cases), and then use Trimmomatic software to perform quality control on the data, remove low-quality sequences and adapters, and use Fastqc software evaluates the data after quality control, and obtains the metagenomic data after quality control;

[0039] S2. MetaPhIAn2 software was used for metagenome species annotation analysis, and the abundance information of intestinal flora species of normal people and colorectal cancer patients was obtained;

[0040] S3. Based on the metagenomic data after quality control in S1 and the abundance information in S2, L...

Embodiment 2

[0048] Compared with Example 1, the difference of this example is that the formula of probiotics in step S6 is: the content of Clostridium butyricum (Clostridium butyricum) is 1×10 9 CFU / ml, the content of Enterococcus faecium is 1×10 8 CFU / ml, the content of Lactobacillus brevis is 1×10 8 CFU / ml, the content of Lactobacillus plantarum is 1×10 8 CFU / ml, the content of Lactobacillus rhamnosus is 1×10 8 CFU / ml, the content of Lactobacillus sakei is 1×10 8 CFU / ml, the content of Leuconostoc mesenteroides is 1×10 8 CFU / ml. The end result is as Figure 6 shown, where Figure 6 -A is the abundance change of probiotics in this embodiment, Figure 6 -B is the abundance change of pathogenic bacteria in the present embodiment (wherein because the abundance of this pathogenic bacteria of Fusobacterium gonidiaformans is significantly higher than other pathogenic bacteria, so the abundance of Fusobacterium gonidiaformans corresponds to the ordinate on the right side of the figure, ...

Embodiment 3

[0050] Compared with Example 1, the difference of this example is that the formula of probiotics in step S6 is: the content of Clostridium butyricum (Clostridium butyricum) is 5×10 10 CFU / ml, the content of Enterococcus faecium is 5×10 9 CFU / ml, the content of Lactobacillus brevis is 5×10 9 CFU / ml, the content of Lactobacillus plantarum is 5×10 9 CFU / ml, the content of Lactobacillus rhamnosus is 5×10 9 CFU / ml, the content of Lactobacillus sakei is 5×10 9 CFU / ml, the content of Leuconostoc mesenteroides is 5×10 9 CFU / ml. The end result is as Figure 7 shown, where Figure 7 -A is the abundance change of probiotics in this embodiment, Figure 7 -B is the abundance change of pathogenic bacteria in the present embodiment (wherein because the abundance of this pathogenic bacteria of Fusobacterium gonidiaformans is significantly higher than other pathogenic bacteria, so the abundance of Fusobacterium gonidiaformans corresponds to the ordinate on the right side of the figure, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a formula of probiotics for inhibiting pathogenic bacteria of colorectal cancer and a screening method thereof. The screening method of the probiotics comprises the following steps: finding the pathogenic bacteria of the colorectal cancer according to metagenome data and abundance of intestinal flora of normal people and colorectal cancer patients, then constructing an intestinal flora interaction network to screen the probiotics capable of inhibiting the pathogenic bacteria of the colorectal cancer, adjusting the proportion of the probiotics, and finally verifying. Theformula of the probiotics obtained by the method is shown in the specification, wherein the content of the clostridium butyricum is 1.3*10 <10> CFU/ml; the content of enterococcus faecalis is 1*10 <9> CFU/ml, the content of lactobacillus brevis is 1*10<9> CFU/ml, the content of lactobacillus plantarum is 1*10 <9> CFU/ml, the content of lactobacillus rhamnosus is 1*10 <9> CFU/ml, the content of lactobacillus sake is 1*10 <9> CFU/ml and the content of leuconostoc mesenteroides is 1*10 <9> CFU/ml. The method disclosed by the invention has the advantages that (1) an intestinal flora interaction network is constructed, so that the screened probiotic formula can be better colonized in intestinal tracts; (2) the obtained probiotic formula does not generate drug resistance, and is safe, effectiveand excellent in performance; and (3) an online warehouse database of human intestinal microbiome is constructed, so that the result is more universal and reliable.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a probiotic formula for inhibiting colorectal cancer pathogenic bacteria and a screening method thereof. Background technique [0002] Colorectal cancer (CRC) is a common malignant tumor in humans and is currently listed as the third most common cancer in the world. With the improvement of people's living standard and the change of diet structure, its morbidity and mortality are on the rise, seriously threatening human health. A large number of studies have reported that CRC is associated with various factors, such as obesity, diabetes, sedentary lifestyle, high-fat diet, smoking, alcoholism, age, gender, family history, etc., but its exact pathogenesis is still unclear. [0003] More and more studies this year have suggested that gut microbiota is a very important factor related to the progression of CRC. Gut flora, as an organoid, has a deep interaction relationship with ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G16B50/30G16B5/00G16B30/00C12N1/20C12R1/145C12R1/01C12R1/24C12R1/25C12R1/225
CPCG16B50/30G16B5/00G16B30/00C12N1/20
Inventor 陈卫华江浦滋吴思成聂庆庆刘智
Owner 君维安(武汉)生命科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap